Mind Medicine (MindMed) Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Money raised funds drug research and commercialization, showing the company needs capital to grow.
Prospectus supplements provide legal documents investors need to understand what they're buying.
Prospectus supplements provide legal documents investors need to understand what they're buying.
Good trial results increase chance a drug gets approved and generates future revenue.
More stock options help attract talent, but dilute existing shareholders' ownership slightly.
Updated presentations keep investors informed about company progress and strategy.
Advancing clinical trials means the company is progressing toward potential FDA approval.
Stocky reads Mind Medicine (MindMed) Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Mind Medicine (MindMed) Inc.'s most recent tracked filing was a 8-K on 24 Jun 2026: Raises $758 million through stock offering at $34 per share.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.